Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baxter International Inc (BAX) vs Infosys Limited (INFY) Price & Performance

Baxter International IncTrade
Infosys LimitedTrade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Infosys Limited — how do they compare? Baxter International Inc trades at $26.94 (market cap $13.93B), while Infosys Limited trades at $12.22 (market cap $49.94B). The key difference: Infosys Limited is far larger — about 3.6× Baxter International Inc's market cap, and Infosys Limited pays the higher dividend (4.26%). Which is the better fit depends on your goals.

BAXINFY
Market Cap
$13.93B$49.94B
Sector
HealthTechnology
52-Week High
$28.35$20.22
52-Week Low
$15.80$10.49
Enterprise Value
$21.45B$47.69B
Dividend Yield
0.15%4.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baxter International Inc

Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.

The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.

Infosys Limited

INFY trades at $12.28, down 2.23% today, with a mixed technical picture showing bullish moving averages but overbought RSI levels. Fundamentally, the company reported Q1 2027 revenue below expectations but maintained strong margins and AI growth, with a P/E of 15.56 and robust ROE of 32.12%. Recent news includes strategic AI collaborations and a CEO transition, while analyst sentiment remains cautious with a consensus price target of $11.05.

The outlook for INFY is balanced; solid profitability and AI adoption offer upside, but near-term revenue softness and elevated valuation pose risks. Investors should weigh strong cash flow and market position against competitive pressures and execution challenges in a volatile IT services market.

Returns comparison

Trailing returns across standard periods

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX

About Infosys Limited

Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.

Read more on INFY